NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

• ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development
• The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia
• NAVER D2SF to strengthen its global healthcare founder community through its healthcare network and go-to-market expertise

SEOUL, South Korea, Sept. 18, 2026 /PRNewswire/ -- NAVER D2SF, NAVER's inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed's $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalized treatment decisions. NAVER D2SF's investment reflects ImpriMed's commercial and clinical experience in the U.S. healthcare market and its growing capabilities across precision medicine and drug development.

Precision oncology increasingly relies on integrating multiple types of patient data to account for differences in disease biology and treatment response. ImpriMed applies multimodal AI to patient-specific cancer cell characteristics, drug response profiles, and clinical information to enable more personalized treatment selection.

At the core of ImpriMed's xCellSense^® platform is its ability to keep patient cancer cells viable ex vivo for extended periods, enabling evaluation of their biological characteristics and drug sensitivity. The platform combines these results with immunophenotypic, genomic, and clinical data to guide treatment decisions. ImpriMed is developing AI models trained on more than 3.5 million data points, combining real-world data with functional cell analysis to improve predictive accuracy.

ImpriMed is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch. The company has also established business partnerships with major U.S. hospitals as it builds its human health presence in North America. In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS) and is progressing through the approval and commercialization process. ImpriMed also collaborates with leading tertiary hospitals, including Catholic University Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Gangneung Asan Hospital.

ImpriMed's human healthcare expansion is supported by its commercial experience in veterinary precision oncology and its growing CRO business in drug development. In veterinary medicine, ImpriMed has performed more than 27,000 tests for canine and feline lymphoma to guide treatment decisions. A retrospective study showed a threefold increase in survival time and a fourfold improvement in treatment response, and the findings have been published in a peer-reviewed scientific journal. ImpriMed's solutions are currently used by more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea.

ImpriMed was co-founded in Silicon Valley by CEO Sungwon Lim and CTO Jamin Koo, who studied together at KAIST and Stanford University. The company brings together expertise in biomedical research, AI modeling, clinical collaboration, and commercialization. Beyond North America, ImpriMed plans to expand into the European and Asian markets.

The $10 million bridge round follows ImpriMed's $23 million Series A in 2023. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, as well as follow-on investments from existing investors BonAngels and Han River Partners.

NAVER D2SF continues to invest in healthcare startups targeting the North American market. Through NAVER D2SF's founder network, portfolio companies such as Soundable Health, PranaQ, and NubiLab share local market knowledge and operating experience, fostering collaboration across R&D and go-to-market strategy.

About NAVER D2SF

NAVER D2SF is NAVER's in-house corporate venture arm, supporting startups through investment and collaboration. Founded in 1999, NAVER has been Korea's leading search engine for more than 20 years and operates across commerce, content, fintech, and cloud services. Guided by its technology vision of D2 (For Developers, By Developers), NAVER continues to develop new technologies and build global partnerships.

To learn more, visit https://d2sf.naver.com.

SOURCE NAVER D2SF